LENZ Therapeutics is a commercial pharmaceutical company that develops and commercializes vision therapies, with its lead product being a once-daily aceclidine-based eye drop designed to treat presbyopia, the age-related loss of near vision that affects a substantial global population. The company generates revenue through direct-to-consumer sales in the U.S. self-pay market, supported by a sales force targeting eye care professionals, while pursuing international expansion through licensing partnerships in multiple regions. The product operates through a pupil-selective mechanism that restores near vision clarity for extended periods without compromising distance vision, offering a differentiated approach compared to alternative miotic treatments and backed by patent protection extending decades into the future.